Cancer immunotherapy using virus particles

• US 10,639,363 B2
• Filed: 05/08/2017
• Issued: 05/05/2020
• Est. Priority Date: 11/07/2014
• Status: Active Grant

• Current Assignee: Case Western Reserve University
• Original Assignee: Case Western Reserve University
• Inventors: Steinmetz, Nicole F., Wen, Amy M., Fiering, Steven, Lizotte, Patrick H.
• Primary Examiner(s): Zou, Nianxiang
• Application Number:
  US15/589,677
• Publication Number:
  US 20180133304A1
• Time in Patent Office: 1,093 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/5258 Virus-like particles
• CPC Class Codes: A61K 2039/544 to the airways
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C12N 2770/00023 Virus like particles [VLP]
• CPC Class Codes: C12N 2770/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/00071 Demonstrated in vivo effect
• CPC Class Codes: C12N 2770/32022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/32023 Virus like particles [VLP]
• CPC Class Codes: C12N 2770/32034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/32071 Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

Claims

1. A method of treating cancer in a subject in need thereof, the method comprising:

administering directly to the cancer a therapeutically effective amount of an in situ vaccine, the in situ vaccine including at least one of potato virus X, or potato virus X virus-like particles, wherein the potato virus X, and potato virus X virus-like particles are not used as a vehicle for drug or antigen delivery.

2. The method of claim 1, wherein the in situ vaccine includes potato virus X virus-like particles.

3. The method of claim 1, wherein the cancer is metastatic cancer.

4. The method of claim 1, wherein the cancer is selected from the group consisting of melanoma, breast cancer, colon cancer, lung cancer, and ovarian cancer.

5. The method of claim 1, wherein the cancer is lung cancer and the in situ vaccine is administered by inhalation.

6. The method of claim 1, further comprising administering a therapeutically effective amount of a chemotherapeutic to the subject.

7. The method of claim 6, wherein the chemotherapeutic is not loaded on or bound to the potato virus X, or potato virus X virus-like particles.

8. The method of claim 6, wherein the chemotherapeutic is doxorubicin.

9. The method of claim 1, wherein the therapeutically effective amount of the in situ vaccine is an amount effective to stimulate a systemic immune response to the cancer in the subject.

10. The method of claim 1, wherein the therapeutically effective amount of the in situ vaccine is an amount effective to promote neutrophil activation or an increase in tumor-infiltrating neutrophils and activated neutrophils.

11. A method of treating melanoma in a subject in need thereof, the method comprising:

administering directly to the melanoma a therapeutically effective amount of an in situ vaccine, the in situ vaccine including at least one of potato virus X, or potato virus X virus-like particles, wherein the potato virus X, and potato virus X virus-like particles are not used as a vehicle for drug or antigen delivery; and

administering a therapeutically effective amount of doxorubicin to the subject, wherein the doxorubicin is not loaded on or bound to the potato virus X, or potato virus X virus-like particles.